Review of Breast Cancer Pathologigcal Image Processing

Breast cancer is one of the most common malignancies. Pathological image processing of breast has become an important means for early diagnosis of breast cancer. Using medical image processing to assist doctors to detect potential breast cancer as early as possible has always been a hot topic in the field of medical image diagnosis. In this paper, a breast cancer recognition method based on image processing is systematically expounded from four aspects: breast cancer detection, image segmentation, image registration, and image fusion. The achievements and application scope of supervised learning, unsupervised learning, deep learning, CNN, and so on in breast cancer examination are expounded. The prospect of unsupervised learning and transfer learning for breast cancer diagnosis is prospected. Finally, the privacy protection of breast cancer patients is put forward.

Download Full-text

Intelligent Segmentation and Recognition Method of Breast Cancer Based on Digital Image Processing Technology

Wireless Communications and Mobile Computing ◽

10.1155/2021/2256316 ◽

2021 ◽

Vol 2021 ◽

pp. 1-9

Author(s):

Xiaochen Tang ◽

Yunbo An ◽

Congshan Li

Keyword(s):

Breast Cancer ◽

Image Processing ◽

Digital Image Processing ◽

Digital Image ◽

Medical Image ◽

Intelligent System ◽

Recognition System ◽

Processing Technology ◽

Image Processing Technology ◽

Pathological Image

With the development of digital image technology, judging diseases by medical image plays an important role in medical diagnosis. Mammography is the most effective imaging examination method for breast cancer at present. Intelligent segmentation and identification of breast cancer images and judging their size and classification by digital image processing technology can promote the development of clinical medicine. This paper introduces the preprocessing technology of breast cancer pathological image and medical image recognition technology of breast cancer. In order to improve the segmentation accuracy of image processing and optimize, the segmentation recognition ability in digital mammography was improved. Based on the technical basis of pathological image analysis of breast cancer, the architecture of intelligent segmentation and recognition system for breast cancer was constructed, and each functional module of intelligent system was introduced in detail. Based on digital image processing technology, filtering technology is used to reduce dryness and improve the clarity of the image. Public datasets INBreast and DDSM-BCRP were used to verify system’s performance, and it was tested on the breast cancer image test set. The experiment shows that the comprehensive performance of the intelligent segmentation and recognition system can realize the segmentation and recognition of breast cancer and has higher accuracy and interpretability, which is helpful to improve the diagnosis of doctors.

Download Full-text

Serum Long Non-Coding RNAs PVT1, HOTAIR, and NEAT1 as Potential Biomarkers in Egyptian Women with Breast Cancer

Biomolecules ◽

10.3390/biom11020301 ◽

2021 ◽

Vol 11 (2) ◽

pp. 301

Author(s):

Amal Ahmed Abd El-Fattah ◽

Nermin Abdel Hamid Sadik ◽

Olfat Gamil Shaker ◽

Amal Mohamed Kamal ◽

Nancy Nabil Shahin

Keyword(s):

Breast Cancer ◽

Logistic Regression ◽

Cancer Patients ◽

Breast Cancer Diagnosis ◽

Serum Levels ◽

Breast Cancer Patients ◽

Multivariate Logistic Regression ◽

Expression Levels ◽

Non Coding Rnas ◽

Pai 1

Long non-coding RNAs play an important role in tumor growth, angiogenesis, and metastasis in several types of cancer. However, the clinical significance of using lncRNAs as biomarkers for breast cancer diagnosis and prognosis is still poorly investigated. In this study, we analyzed the serum expression levels of lncRNAs PVT1, HOTAIR, NEAT1, and MALAT1, and their associated proteins, PAI-1, and OPN, in breast cancer patients compared to fibroadenoma patients and healthy subjects. Using quantitative real-time PCR (qRT-PCR), we compared the serum expression levels of the four circulating lncRNAs in patients with breast cancer (n = 50), fibroadenoma (n = 25), and healthy controls (n = 25). The serum levels of PAI-1 and OPN were measured using ELISA. Receiveroperating-characteristic (ROC) analysis and multivariate logistic regression were used to evaluate the diagnostic value of the selected parameters. The serum levels of HOTAIR, PAI-1, and OPN were significantly higher in breast cancer patients compared to controls and fibroadenoma patients. The serum level of PVT1 was significantly higher in breast cancer patients than in the controls, while that of NEAT1 was significantly lower in breast cancer patients compared to controls and fibroadenoma patients. Both ROC and multivariate logistic regression analyses revealed that PAI-1 has the greatest power in discriminating breast cancer from the control, whereas HOTAIR, PAI-1, and OPN have the greatest power in discriminating breast cancer from fibroadenoma patients. In conclusion, our data suggest that the serum levels of PVT1, HOTAIR, NEAT1, PAI-1, and OPN could serve as promising diagnostic biomarkers for breast cancer.

Download Full-text

What mediates the racial/ethnic disparity in psychosocial stress among breast cancer patients?

Cancer Causes & Control ◽

10.1007/s10552-021-01392-7 ◽

2021 ◽

Author(s):

C. T. Sánchez-Díaz ◽

S. Strayhorn ◽

S. Tejeda ◽

G. Vijayasiri ◽

G. H. Rauscher ◽

...

Keyword(s):

Breast Cancer ◽

Social Support ◽

Cancer Patients ◽

Cancer Diagnosis ◽

Psychosocial Stress ◽

Breast Cancer Diagnosis ◽

Support Needs ◽

Breast Cancer Patients ◽

Hispanic Patients ◽

Racial Ethnic

Abstract Background Prior studies have observed greater levels of psychosocial stress (PSS) among non-Hispanic (nH) African American and Hispanic women when compared to nH White patients after a breast cancer diagnosis. We aimed to determine the independent and interdependent roles of socioeconomic position (SEP) and unmet support in the racial disparity in PSS among breast cancer patients. Methods Participants were recruited from the Breast Cancer Care in Chicago study (n = 989). For all recently diagnosed breast cancer patients, aged 25–79, income, education, and tract-level disadvantage and affluence were summed to create a standardized socioeconomic position (SEP) score. Three measures of PSS related to loneliness, perceived stress, and psychological consequences of a breast cancer diagnosis were defined based on previously validated scales. Five domains of unmet social support needs (emotional, spiritual, informational, financial, and practical) were defined from interviews. We conducted path models in MPlus to estimate the extent to which PSS disparities were mediated by SEP and unmet social support needs. Results Black and Hispanic patients reported greater PSS compared to white patients and greater unmet social support needs (p = 0.001 for all domains). Virtually all of the disparity in PSS could be explained by SEP. A substantial portion of the mediating influence of SEP was further transmitted by unmet financial and practical needs among Black patients and by unmet emotional needs for Hispanic patients. Conclusions SEP appeared to be a root cause of the racial/ethnic disparities in PSS within our sample. Our findings further suggest that different interventions may be necessary to alleviate the burden of SEP for nH AA (i.e., more financial support) and Hispanic patients (i.e., more emotional support).

Download Full-text

COVID-related anxiety is prevalent and accurately reflects serious COVID risks in breast cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.12053 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 12053-12053

Author(s):

Marisa C. Weiss ◽

Stephanie Kjelstrom ◽

Meghan Buckley ◽

Adam Leitenberger ◽

Melissa Jenkins ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Cancer Diagnosis ◽

Breast Cancer Diagnosis ◽

P Value ◽

Breast Cancer Patients ◽

Chi Square ◽

Liver And Kidney ◽

Chi Square Test ◽

A Current

12053 Background: A current cancer diagnosis is a risk factor for serious COVID-19 complications (CDC). In addition, the pandemic has caused major disruptions in medical care and support networks, resulting in treatment delays, limited access to doctors, worsening health disparities, social isolation; and driving higher utilization of telemedicine and online resources. Breastcancer.org has experienced a sustained surge of new and repeat users seeking urgent information and support. To better understand these unmet needs, we conducted a survey of the Breastcancer.org Community. Methods: Members of the Breastcancer.org Community were invited to complete a survey on the effects of the COVID-19 pandemic on their breast cancer care, including questions on demographics, comorbidities (including lung, heart, liver and kidney disease, asthma, diabetes, obesity, and other chronic health conditions); care delays, anxiety due to COVID-related care delays, use of telemedicine, and satisfaction with care during COVID. The survey was conducted between 4/27/2020-6/1/2020 using Survey Monkey. Results were tabulated and compared by chi square test. A p-value of 0.05 is considered significant. Data were analyzed using Stata 16.0 (Stata Corp., Inc, College Station, TX). Results: Our analysis included 568 breast cancer patients of whom 44% had ≥1 other comorbidities associated with serious COVID-19 complications (per CDC) and 37% had moderate to extreme anxiety about contracting COVID. This anxiety increased with the number of comorbidities (p=0.021), age (p=0.040), and with a current breast cancer diagnosis (p=0.011) (see table). Anxiety was significantly higher in those currently diagnosed, ≥65, or with ≥3 other comorbidities, compared to those diagnosed in the past, age <44, or without other comorbidities. Conclusions: Our survey reveals that COVID-related anxiety is prevalent at any age regardless of overall health status, but it increased with the number of other comorbidities, older age, and a current breast cancer diagnosis. Thus, reported anxiety is proportional to the risk of developing serious complications from COVID. Current breast cancer patients of all ages—especially with other comorbidities—require emotional support, safe access to their providers, and prioritization for vaccination.[Table: see text]

Download Full-text

Abstract P148: Heart Disease Among Breast Cancer Patients

Circulation ◽

10.1161/circ.137.suppl_1.p148 ◽

2018 ◽

Vol 137 (suppl_1) ◽

Author(s):

Tekeda F Ferguson ◽

Sunayana Kumar ◽

Denise Danos

Keyword(s):

Breast Cancer ◽

Heart Disease ◽

Electronic Health Records ◽

Cancer Patients ◽

Cancer Diagnosis ◽

Breast Cancer Diagnosis ◽

Health Concern ◽

Breast Cancer Patients ◽

Health Records ◽

Electronic Health

Purpose: In conjunction with women being diagnosed earlier with breast cancer and a rapidly aging population, advances in cancer therapies have swiftly propelled cardiotoxicity as a major health concern for breast cancer patients. Frequent cardiotoxicity outcomes include: reduced left ventricular ejection fraction (LVEF), myocardial infarction, asymptomatic or hospitalized heart failure, arrhythmias, hypertension, and thromboembolism. The purpose of this study was to use an electronic health records system determine if an increased odds of heart disease was present among women with breast cancer. Methods: Data from the Research Action for Health Network (REACHnet) was used for the analysis. REACHnet is a clinical data research network that uses the common data model to extract electronic health records (EHR) from health networks in Louisiana (n=100,000).Women over the age of 30 with data (n=35,455) were included in the analysis. ICD-9 diagnosis codes were used to classify heart disease (HD) (Hypertensive HD, Ischemic HD, Pulmonary HD, and Other HD) and identify breast cancer patients. Additional EHR variables considered were smoking status, and patient vitals. Chi-square tests, crude, and adjusted logistic regression models were computed utilizing SAS 9.4. Results: Utilizing diagnoses codes our study team has estimated 28.6% of women over the age of 30 with a breast cancer diagnosis (n=816) also had a heart disease diagnosis, contrasted with 15.6% of women without a breast cancer diagnosis. Among patients with heart disease, there was no significant difference in the distribution of the type of heart disease diagnoses by breast cancer status (p=0.87). There was a 2.21 (1.89, 2.58) crude odds ratio of having a CVD diagnoses among breast cancer cases when referenced to cancer free women. After adjusting for age (30-49, 50-64, 65+), race (black/white), and comorbidities (obesity/overweight, diabetes, current smoker) there was an increased risk of heart disease (OR: 1.24 (1.05, 1.47)). Conclusion: The short-term and long-term consequences of cardiotoxicity on cancer treatment risk-to-benefit ratio, survivorship issues, and competing causes of mortality are increasingly being acknowledged. Our next efforts will include making advances in predictive risk modeling. Maximizing benefits while reducing cardiac risks needs to become a priority in oncologic management and monitoring for late-term toxic effects.

Download Full-text

The influence of coping types on post-traumatic growth in patients with primary breast cancer

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyaa159 ◽

2020 ◽

Vol 51 (1) ◽

pp. 85-91

Author(s):

Tomomi Fujimoto ◽

Hitoshi Okamura

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Japanese Version ◽

Breast Cancer Diagnosis ◽

Well Being ◽

Proactive Coping ◽

Breast Cancer Patients ◽

Post Traumatic Growth ◽

Post Traumatic ◽

Mental Well Being

Abstract Background The physical and mental impacts of breast cancer diagnosis on women are substantial. Several studies have investigated the negative mental health effects of breast cancer. However, in recent years, there has also been growing interest in post-traumatic growth, a positive response to stressful events. Considering positive psychology focuses on such virtues, proactive coping theory was chosen as a theoretical guide. This study investigates how breast cancer patients’ post-traumatic growth is associated with proactive coping and mental well-being. Methods A self-administered questionnaire survey was conducted with 80 breast cancer patients aged 20–70 years attending an outpatient clinic. The survey was conducted using the Posttraumatic Growth Inventory-Japanese version (PTGI-J), Proactive Coping Inventory-Japanese version and the Japanese version of the General Health Questionnaire. Single regression and multiple regression analyses with PTGI-J as the dependent variable were performed. Results The multiple regression analysis extracted proactive coping (P = 0.006), emotional support seeking (P = 0.004) and avoidance coping (P = 0.001) as factors associated with post-traumatic growth in breast cancer patients. Conclusions These results suggest that using proactive coping for conflicts caused by a breast cancer diagnosis and temporary avoidant coping for daily stresses during the treatment process may enhance post-traumatic growth while preventing deterioration in mental well-being. Additionally, seeking emotional support is important for post-traumatic growth.

Download Full-text

The role of polygenic risk and susceptibility genes in breast cancer over the course of life

Nature Communications ◽

10.1038/s41467-020-19966-5 ◽

2020 ◽

Vol 11 (1) ◽

Author(s):

Nina Mars ◽

◽

Elisabeth Widén ◽

Sini Kerminen ◽

Tuomo Meretoja ◽

...

Keyword(s):

Breast Cancer ◽

Risk Assessment ◽

Positive Family History ◽

Breast Cancer Diagnosis ◽

Risk Scores ◽

Limited Information ◽

Breast Cancer Patients ◽

Polygenic Risk ◽

First Degree Relatives ◽

Fold Enrichment

AbstractPolygenic risk scores (PRS) for breast cancer have potential to improve risk prediction, but there is limited information on their utility in various clinical situations. Here we show that among 122,978 women in the FinnGen study with 8401 breast cancer cases, the PRS modifies the breast cancer risk of two high-impact frameshift risk variants. Similarly, we show that after the breast cancer diagnosis, individuals with elevated PRS have an elevated risk of developing contralateral breast cancer, and that the PRS can considerably improve risk assessment among their female first-degree relatives. In more detail, women with the c.1592delT variant in PALB2 (242-fold enrichment in Finland, 336 carriers) and an average PRS (10–90th percentile) have a lifetime risk of breast cancer at 55% (95% CI 49–61%), which increases to 84% (71–97%) with a high PRS ( > 90th percentile), and decreases to 49% (30–68%) with a low PRS ( < 10th percentile). Similarly, for c.1100delC in CHEK2 (3.7–fold enrichment; 1648 carriers), the respective lifetime risks are 29% (27–32%), 59% (52–66%), and 9% (5–14%). The PRS also refines the risk assessment of women with first-degree relatives diagnosed with breast cancer, particularly among women with positive family history of early-onset breast cancer. Here we demonstrate the opportunities for a comprehensive way of assessing genetic risk in the general population, in breast cancer patients, and in unaffected family members.

Download Full-text

Interval breast cancer is associated with other types of tumors

Nature Communications ◽

10.1038/s41467-019-12652-1 ◽

2019 ◽

Vol 10 (1) ◽

Cited By ~ 4

Author(s):

Felix Grassmann ◽

Wei He ◽

Mikael Eriksson ◽

Marike Gabrielson ◽

Per Hall ◽

...

Keyword(s):

Breast Cancer ◽

Genetic Risk Score ◽

Breast Cancer Diagnosis ◽

Cancer Genes ◽

Common Variants ◽

Breast Cancer Patients ◽

Interval Breast Cancer ◽

Increased Risk ◽

History Of ◽

Screening And Prevention

Abstract Breast cancer (BC) patients diagnosed between two screenings (interval cancers) are more likely than screen-detected patients to carry rare deleterious mutations in cancer genes potentially leading to increased risk for other non-breast cancer (non-BC) tumors. In this study, we include 14,846 women diagnosed with BC of which 1,772 are interval and 13,074 screen-detected. Compared to women with screen-detected cancers, interval breast cancer patients are more likely to have a non-BC tumor before (Odds ratio (OR): 1.43 [1.19–1.70], P = 9.4 x 10−5) and after (OR: 1.28 [1.14–1.44], P = 4.70 x 10−5) breast cancer diagnosis, are more likely to report a family history of non-BC tumors and have a lower genetic risk score based on common variants for non-BC tumors. In conclusion, interval breast cancer is associated with other tumors and common cancer variants are unlikely to be responsible for this association. These findings could have implications for future screening and prevention programs.

Download Full-text

Breast cancer survivors’ perspectives on whether clinical staff should ask breast cancer patients about childhood abuse

Annals of The Royal College of Surgeons of England ◽

10.1308/003588414x13946184901407 ◽

2014 ◽

Vol 96 (5) ◽

pp. 364-368

Author(s):

L Clark ◽

C Holcombe ◽

J Fisher ◽

P Salmon

Keyword(s):

Breast Cancer ◽

Childhood Abuse ◽

Breast Cancer Survivors ◽

Breast Cancer Diagnosis ◽

Clinical Staff ◽

Breast Cancer Patients ◽

Patient Support Group ◽

Increased Risk ◽

Research Findings ◽

Programme Of Care

Introduction Recent studies have shown that women who recall childhood abuse are at increased risk of emotional problems following a breast cancer diagnosis. How services should respond is unclear given the risk of compounding the emotional trauma of cancer with questioning about abuse. Our aim was to present the research findings to women with experience of breast cancer so as to obtain their perspective on how this evidence should influence clinical practice. Methods Participants were women who had been treated for breast cancer at one of the study units and women with a history of breast cancer who were members of a local patient support group. Three focus groups were conducted (with six, five and three participants respectively). The interview transcripts were analysed qualitatively. Results Participants emphasised the importance of the research findings for cancer care. The consensus was that abuse and its consequences for patients being treated for cancer should not be a ‘taboo’ area, and that patients should be given the opportunity and choice to disclose abuse as part of a holistic programme of care. Conclusions Services should examine how to include prompts about abuse as part of routine holistic assessment by clinical staff, who will need to be trained in eliciting and managing disclosures of abuse.

Download Full-text

Multiplatform Investigation of Plasma and Tissue Lipid Signatures of Breast Cancer Using Mass Spectrometry Tools

International Journal of Molecular Sciences ◽

10.3390/ijms21103611 ◽

2020 ◽

Vol 21 (10) ◽

pp. 3611

Author(s):

Alex Ap. Rosini Silva ◽

Marcella R. Cardoso ◽

Luciana Montes Rezende ◽

John Q. Lin ◽

Fernando Guimaraes ◽

...

Keyword(s):

Breast Cancer ◽

Mass Spectrometry ◽

Tissue Injury ◽

Desorption Electrospray Ionization ◽

Breast Cancer Diagnosis ◽

Molecular Signature ◽

Cancer Tissue ◽

Plasma Samples ◽

Tissue Lipid ◽

Breast Cancer Patients

Plasma and tissue from breast cancer patients are valuable for diagnostic/prognostic purposes and are accessible by multiple mass spectrometry (MS) tools. Liquid chromatography-mass spectrometry (LC-MS) and ambient mass spectrometry imaging (MSI) were shown to be robust and reproducible technologies for breast cancer diagnosis. Here, we investigated whether there is a correspondence between lipid cancer features observed by desorption electrospray ionization (DESI)-MSI in tissue and those detected by LC-MS in plasma samples. The study included 28 tissues and 20 plasma samples from 24 women with ductal breast carcinomas of both special and no special type (NST) along with 22 plasma samples from healthy women. The comparison of plasma and tissue lipid signatures revealed that each one of the studied matrices (i.e., blood or tumor) has its own specific molecular signature and the full interposition of their discriminant ions is not possible. This comparison also revealed that the molecular indicators of tissue injury, characteristic of the breast cancer tissue profile obtained by DESI-MSI, do not persist as cancer discriminators in peripheral blood even though some of them could be found in plasma samples.

Download Full-text